Method of treating melanoma
US6573284B1 · kind B1 · utility
31Cited by
5References
8Claims
0Family size
Inventors
Key dates
| Filing date | Jun 14, 1999 |
| Grant date | Jun 3, 2003 |
| Priority date | — |
| Expiry date | Jun 14, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D317/58
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel pro-drugs and assay reagents are provided which are useful as therapeutic agents especially for delivery and targetting therapeutically active agents to melanoma cells. The pro-drugs and assay reagents are substrates for tyrosinase and may be represented by the formula TyrX—B—ThrAg*. The compounds of formula TyrX—B—ThrAg* are capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location. TyrX— being a residue of an optionally substituted tyrosine analogue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.